MAYTANSINE

MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.

Cross Reference

Introduction

To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with MAYTANSINE?

MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with MAYTANSINE

MeSH term MeSH ID Detail
Breast Neoplasms D001943 24 associated lipids
Lung Neoplasms D008175 171 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Body Weight D001835 333 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Melanoma D008545 69 associated lipids
Brain Diseases D001927 27 associated lipids
Leukemia P388 D007941 43 associated lipids
Hyperplasia D006965 34 associated lipids
Leukemia D007938 74 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Bronchial Spasm D001986 18 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Asthenia D001247 5 associated lipids
Hypopharyngeal Neoplasms D007012 1 associated lipids
Per page 10 20 | Total 17

PubChem Associated disorders and diseases

What pathways are associated with MAYTANSINE

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with MAYTANSINE?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with MAYTANSINE?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with MAYTANSINE?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with MAYTANSINE?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with MAYTANSINE?

Xenograft Model

Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with MAYTANSINE

Download all related citations
Per page 10 20 50 100 | Total 611
Authors Title Published Journal PubMed Link
Géraud A et al. Preliminary results of the concurrent use of radiotherapy for bone metastases and trastuzumab emtansine in patients with HER2-positive metastatic breast cancer. 2016 Cancer Radiother pmid:27342941
Dzimitrowicz H et al. T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab. 2016 J. Clin. Oncol. pmid:27298406
Wang C et al. Chromatography-based methods for determining molar extinction coefficients of cytotoxic payload drugs and drug antibody ratios of antibody drug conjugates. 2016 J Chromatogr A pmid:27286648
Hamblett KJ et al. Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability. 2016 Mol. Pharm. pmid:27248573
Ponte JF et al. Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates. 2016 Bioconjug. Chem. pmid:27174129
Fan Y et al. Effects of modulation of pentose-phosphate pathway on biosynthesis of ansamitocins in Actinosynnema pretiosum. 2016 J. Biotechnol. pmid:27173582
Jacot W et al. Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. 2016 Breast Cancer Res. Treat. pmid:27167986
Sandra K et al. Multiple heart-cutting and comprehensive two-dimensional liquid chromatography hyphenated to mass spectrometry for the characterization of the antibody-drug conjugate ado-trastuzumab emtansine. 2016 J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. pmid:27160547
Milowsky MI et al. Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. 2016 Urol. Oncol. pmid:27765518
Walles M et al. New Insights in Tissue Distribution, Metabolism, and Excretion of [3H]-Labeled Antibody Maytansinoid Conjugates in Female Tumor-Bearing Nude Rats. 2016 Drug Metab. Dispos. pmid:27122302
Ogitani Y et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. 2016 Clin. Cancer Res. pmid:27026201
Baselga J et al. Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer. 2016 Clin. Cancer Res. pmid:26920887
Martínez MT et al. Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature. 2016 Crit. Rev. Oncol. Hematol. pmid:26318092
Force J et al. Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine. 2016 J. Clin. Oncol. pmid:24778392
T-DM1 Combo Graduates from I-SPY 2. 2016 Cancer Discov pmid:27095360
Singh AP et al. Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1). 2016 AAPS J pmid:27029797
Shen K et al. Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: a Meta-analysis. 2016 Sci Rep pmid:26979925
Krop IE et al. Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer. 2016 Breast Cancer Res. pmid:26979312
de Goeij BE and Lambert JM New developments for antibody-drug conjugate-based therapeutic approaches. 2016 Curr. Opin. Immunol. pmid:26963132
Maass KF et al. Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design. 2016 AAPS J pmid:26912181
Vankemmelbeke M and Durrant L Third-generation antibody drug conjugates for cancer therapy--a balancing act. 2016 Ther Deliv pmid:26893243
Raja SM et al. Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition. 2016 Oncotarget pmid:26859680
Kan S et al. Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells. 2015 BMC Cancer pmid:26475267
Montero JC et al. Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling. 2015 Oncotarget pmid:26336133
Gébleux R et al. Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates. 2015 Mol. Cancer Ther. pmid:26294742
Storz U Antibody-drug conjugates: Intellectual property considerations. 2015 MAbs pmid:26292154
Nguyen M et al. Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma. 2015 Clin. Cancer Res. pmid:26240273
Chung YC et al. Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1). 2015 PLoS ONE pmid:26172389
Beerli RR et al. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency. 2015 PLoS ONE pmid:26132162
van Geel R et al. Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody-Drug Conjugates. 2015 Bioconjug. Chem. pmid:26061183
Miranda Romero P and Marín Gil R Trastuzumab emtansine in locally advanced or metastatic HER2 positive breast cancer; GENESIS-SEFH drug evaluation report. 2015 Farm Hosp pmid:26005893
Esteva FJ et al. What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience? 2015 Am Soc Clin Oncol Educ Book pmid:25993162
Hamblett KJ et al. AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma. 2015 Mol. Cancer Ther. pmid:25931519
Yabe N et al. [A Case of Advanced Breast Cancer in Which Marked Improvement of Joint Pain Was Obtained with Stepwise Dose Reduction of Trastuzumab Emtansine (T-DM1)]. 2015 Gan To Kagaku Ryoho pmid:26805183
Müller P et al. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. 2015 Sci Transl Med pmid:26606967
Eisenstein M Medicine: Eyes on the target. 2015 Nature pmid:26580159
Kan S et al. Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine. 2015 Oncol. Rep. pmid:25976081
Dholaria B and Srinivasan S T-DM1-related carotenoderma and hand-foot syndrome. 2015 Lancet pmid:25933279
Ahmed S et al. HER2-directed therapy: current treatment options for HER2-positive breast cancer. 2015 Breast Cancer pmid:25634227
Foglietta J et al. Letter to the editor concerning 'Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA'. 2015 Ann. Oncol. pmid:25632067
Wiggins B et al. Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody-drug conjugates. 2015 J Pharm Sci pmid:25631158
Lai KC et al. Evaluation of Targets for Maytansinoid ADC Therapy Using a Novel Radiochemical Assay. 2015 Pharm. Res. pmid:25630819
Li T et al. Improvement of ansamitocin P-3 production by Actinosynnema mirum with fructose as the sole carbon source. 2015 Appl. Biochem. Biotechnol. pmid:25564203
Carneiro BA et al. Emerging therapeutic targets in bladder cancer. 2015 Cancer Treat. Rev. pmid:25498841
Mang Y et al. Efficient elimination of CD103-expressing cells by anti-CD103 antibody drug conjugates in immunocompetent mice. 2015 Int. Immunopharmacol. pmid:25467246
Kalsi R et al. Brain metastasis and response to ado-trastuzumab emtansine: a case report and literature review. 2015 Clin. Breast Cancer pmid:25454740
Sibaud V et al. T-DM1-related telangiectasias: a potential role in secondary bleeding events. 2015 Ann. Oncol. pmid:25403586
Yamamoto H et al. Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer. 2015 Jpn. J. Clin. Oncol. pmid:25332421
Singh JC and Lichtman SM Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients. 2015 Drugs Aging pmid:26645293
Hamblett KJ et al. SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm. 2015 Cancer Res. pmid:26631267